Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3021% above fair value
$0.80−0.12 (-13.07%)
Close on Nov 16, 2026Market cap $201.09MP/E –Yield –
Lineage Cell Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Lineage Cell Therapeutics's price to sales ratio was 21.5× on Nov 11, 2026, against 37.5× a year earlier. Over the last 5 years it ranged from 10.5× to 117.0×, with a median of 21.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 21.5× | −14.1 |
| 2025 | Dec 31, 2025 | 35.6× | +24.7 |
| 2024 | Dec 31, 2024 | 10.9× | −10.9 |
| 2023 | Dec 29, 2023 | 21.7× | +7.5 |
| 2022 | Dec 30, 2022 | 14.2× | −102.7 |
| 2021 | Dec 31, 2021 | 117.0× | +19.6 |
| 2020 | Dec 31, 2020 | 97.3× | +53.4 |
| 2019 | Dec 31, 2019 | 44.0× | +21.6 |
| 2018 | Dec 31, 2018 | 22.4× | −49.8 |
| 2017 | Dec 29, 2017 | 72.2× | +7.9 |
| 2016 | Dec 30, 2016 | 64.3× | +10.8 |
| 2015 | Dec 31, 2015 | 53.5× | −4.1 |
| 2014 | Dec 31, 2014 | 57.6× | −8.2 |
| 2013 | Dec 31, 2013 | 65.9× | +27.7 |
| 2012 | Dec 31, 2012 | 38.1× | −30.1 |
| 2011 | Dec 30, 2011 | 68.2× | – |
See a number that looks wrong?